^
    Back
    Association details:
    Biomarker:ER-L
    Cancer:Breast Cancer
    Drug Class:Aromatase inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Breast
    Title:

    Adjuvant endocrine therapy in patients with estrogen receptor-low positive breast cancer: A prospective cohort study

    Published date:
    09/30/2022
    Excerpt:
    Patients were classified into three groups based on the regimen and duration of ET. The regimens included aromatase inhibitor (AI) monotherapy or sequential tamoxifen followed by an AI (AI/T + AI), or only tamoxifen and no ET….For ER-low patients, findings suggest that ET with AI/T + AI may be a reasonable treatment alternative. This effect should be assessed in randomized studies.
    Secondary therapy:
    tamoxifen
    DOI:
    10.1016/j.breast.2022.09.008